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Abstract
Background: Acupuncture is beneficial for controlling chemotherapy-induced nausea and vomiting (CINV).
However, the effect of different acupoint combinations on controlling CINV remains unknown. This study aims to
compare the effects of distal-proximal point association and local distribution point association on controlling CINV.
Methods/design: The study is a single-center, randomized controlled trial. A total of 240 participants will be randomly
divided into four groups. The control group will receive standard antiemetic only, whereas three acupuncture groups
will receive four electro-acupuncture treatments once a day with the standard antiemetic. Acupuncture group I and II
will receive distal-proximal point association (“Neiguan (PC6) and Zhongwan (CV12)”, and “Zusanli (ST36) and CV12”,
respectively); Acupuncture group III will receive local distribution point association (“Shangwan (CV13) and CV12”). The
primary outcome measures are the frequency and distress of nausea and vomiting. The secondary outcome measures
are the grade of constipation and diarrhea, electrogastrogram, quality of life, etc. Assessment is scheduled from the day
before chemotherapy to the fifth day of chemotherapy. Follow-ups are performed from the sixth day to the twenty-
first day of chemotherapy.
Discussion: Results of this trial will help in evaluating the efficacy and safety of electro-acupuncture with different
acupoint combinations in the management of CINV.
Trial registration: ClinicalTrials.gov identifier: NCT02478047.
Keywords: Acupuncture, Chemotherapy-induced nausea and vomiting, Acupoint combination, Randomized
controlled trial
Background
Chemotherapy-induced nausea and vomiting (CINV) are
common side-effects of many antineoplastic regimens
and can occur for several days after treatment [1]. CINV
significantly impacts the patient’ quality of life and nutri-
tional status, and may lead to dose reduction or treat-
ment discontinuation, subsequently increasing the risk
of disease progression [2]. Although effective guidelines
for CINV prevention exist for both moderately and
highly emetogenic chemotherapies, adherence to these
guidelines is not widely practiced because of their
expensive costs and side-effects, such as headaches,
dizziness, constipation, and insomnia [1].
Acupuncture treatment is one of the most sought-after
therapeutic modalities in complementary and alternative
medicine [3]. It is a safe medical procedure with minimal
side effects. Evidence for the therapeutic effects of
acupuncture on CINV exists [4]. Electroacupuncture for
CINV management has been recommended by the
American Society of Clinical Oncology [5]. Based on
Traditional Chinese Medicine (TCM), the combination
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of acupoints can strengthen the essential and compre-
hensive therapeutic effects of acupuncture [6]. However,
no consensus currently exists on the optimal acupoint
combination for controlling CINV. For example, Gottschl-
ing S [7] found that stimulating PC6 (Neiguan), CV12
(Zhongwan), ST36 (Zusanli) and LI4 (Hegu) may effect-
ively prevent CINV; Shen J [8] concluded that electro-
acupuncture on PC6 (Neiguan) and ST36 (Zusanli) is
more effective in controlling emesis than antiemetic
pharmacotherapy alone. Therefore, we propose a random-
ized, controlled trial to determine the optimal combin-
ation of acupoints for CINV management.
In this trial, we aim to determine whether different
acupoint combinations similarly manage CINV. We also
aim to determine whether distal-proximal point associ-




This study aims to: (1) assess the clinical efficacy and
safety of distal-proximal point association and local
distribution point association by electro-acupuncture for
CINV management; (2) assess the patients’ quality of
life, anxiety, and depression, as well as other side effects
of chemotherapy, such as diarrhea and constipation.
Hypothesis
According to the theory of TCM, the combination of
acupoints can achieve a synergistic effect. In addition,
distal-proximal point association and local distribution
point association are the classic methods for combinating
acupoints. We hypothesize that distal-proximal point as-
sociation will achieve better therapeutic effect by reducing
toxicity and enhance efficacy in CINV management.
Design
This is a four-armed parallel randomized controlled trial
(RCT). 240 participants will be randomly assigned to
four groups (a control group and three acupuncture
groups) through central randomization in a 1:1:1:1 ratio.
The flow chart is shown in Fig. 1.
Recruitment
All participants will be recruited from the Tianjin
Medical University Cancer Institute and Hospital, and
the clinical trial information will be posted on notice
boards of the hospital. Our trial started on June 2015,
and the first participant was recruited on 26 June 2015.
For eligible participants who meet all required cri-
teria, it will be requested to sign the written informed
consent before randomization, meanwhile they will be
given enough time to decide whether they willing to
join this study.
Inclusion and exclusion criteria
Inclusion criteria
Participants who meet all of the following criteria will be
considered for enrollment. The inclusion criteria are as
follows: (1) Diagnosed with cancer and need chemother-
apy. (2) The score of Karnofsky (KPS) ≥ 70. (3) Between
18 and 80 years old (either sex). (4) Receiving chemother-
apy as outpatients or inpatients. (5) Receiving chemother-
apy for one or multiple cycles, but the patient will be
taken into the study only once. (6) Patients receiving
chemotherapy containing cis-platinum (cis-platinum ≥
75 mg/m2) or antharcycline-combined chemotherapy
(doxorubicin ≥ 40 mg/m2 or epirubicin ≥ 60 mg/m2). (7)
Life expectancy ≥ 6 months. (8) Willing to participate in
the study and be randomly allocated into one of the four
study groups.
Exclusion criteria
Participants who meet any of the following will be ex-
cluded: (1) Receiving radiotherapy concurrently with
chemotherapy. (2) Gastrointestinal tumors. (3) Liver dis-
ease with serious complications, or with serious abnormal
hepatorenal function (glutamic oxalacetic transaminase
Fig. 1 Flow chart of the study
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(AST), glutamic-pyruvic transaminase (ALT), or total bili-
rubin (TBIL) three times higher than normal, blood urea
nitrogen (BUN) or urine creatinine (Cr) two times higher
than normal). (4) Presence of cardiac pacemaker. (5) Ac-
tive skin infection. (6) Nausea and/or vomiting resulting
from opioids or metabolic imbalances, such as electrolyte
disturbances. (7) Unable to provide self-care or communi-
cate, or have mental illness. (8) Nausea and/or vomiting
resulting from mechanical risk factors, such as, intestinal
obstructions. (9) Brain metastases or intracranial hyper-
tension. (10) Pregnant or lactating.
Randomization
After signing an informed consent and evaluating the
inclusion and exclusion criteria, participants will be
randomly assigned to one of four groups by center
randomization. The central randomized system will be
used and performed by the Clinical Evaluation Center at
China Academy of Chinese Medical Science in Beijing.
A random number and group assignment will be immedi-
ately obtained through the website at http://118.144.35.11/
crivrs/index.htm. Then the practitioner will assign the par-
ticipant to that intervention and the evaluator will perform
a baseline evaluation.
Blinding
The evaluator and the statistician are blinded to the
intervention a participant accepts. Acupuncturists and
patients are not blinded to the treatments they deliver
because of the nature of the intervention.
Intervention
There are four arms in this randomized controlled trial.
The control group is supplied with standard antiemetic
alone, and the other three arms consist of antiemetic
drug and acupuncture.
Control groups
Participants in the control group received standard anti-
emetic alone. Standard antiemetic for all groups is based
on the American Society of Clinical Oncology Clinical
Practice Guideline [9]. 5-hydroxytryptamine-3 (5-HT3)
antagonist (Ramosetron, Tropisetron) and dexametha-
sone will be administered before the chemotherapy
treatment.
Acupuncture groups
Three acupuncture groups will receive electro-acupuncture
with different acupoint combinations: Acupuncture group I
and II will receive distal-proximal point association, and
Acupuncture group III will receive local distribution point
association. The acupuncturists are the members who hold
a Chinese medicine practitioner license from the Ministry
of Health of the People’s Republic of China.
Acupuncture group I: acupoints “PC6+ CV12” plus
antiemetic drug Participants in Acupuncture group I
will receive electro-acupuncture at the Neiguan (PC6)
point and Zhongwan (CV12) point. The location of
Neiguan (PC6) is on the anterior aspect of the forearm,
between the tendons of the palmaris longus and the
flexor carpi radialis, 2 B-cun proximal to the palmar
wrist crease [10]. The location of Zhongwan (CV12) is
on the upper abdomen, 4 B-cun superior to the center
of the umbilicus, on the anterior median line [10].
Acupuncture group II: acupoints “ST36+ CV12” plus
antiemetic drug Participants in Acupuncture group II
will receive electroacupunture at Zusanli (ST36) and
Zhongwan (CV12) points. The location of Zusanli
(ST36) is on anterior aspect of the leg, on the line
connecting ST35 with ST41, 3 B-cun inferior to ST35
[10]. The location of Zhongwan (CV12) has been in-
troduced above.
Acupuncture group III: acupoints “CV12+ CV13”
plus antiemetic drug Participants in Acupuncture
group III will receive electroacupuncture at Zhongwan
(CV12) point and Shangwan (CV13) points. The loca-
tion of Shangwan (CV13) is on the upper abdomen, 5 B-
cun superior to the center of the umbilicus, on the
anterior median line [10]. The location of Zhongwan
(CV12) has been introduced above.
Disposable, stainless steel acupuncture needles will be
used in this trial. The acupuncturists will first insert nee-
dles into the acupoints, then the needles will be manipu-
lated until“de qi”sensation is achieved. Next, the needle
will be connected to an electroacupuncture apparatus.
The positive pole is linked to the needle, and the reference
pole is secured approximately one cm in the proximity of
the acupoint with a plaster. The electro-acupuncture
treatment will use a frequency of 2/10 Hz, and the
intensity of stimulation will be adjusted according to
the patient’s tolerance. The electric current will be set
at less than 10 mA. The procedure will last for
30 min. Treatment is scheduled to occur 30–60 min
before chemotherapy infusion and will last for 4 days.
Detailed information on acupuncture treatment is
summarized based on the revised STRICTA recom-
mendations [11] in Table 1.
Participant timeline
Enrollment will be conducted the day before chemo-
therapy (day 0). The electro -acupuncture intervention
will be given once daily from day 1 to day 4. The sched-
ule of enrollment, interventions, and assessments is
shown in Table 2.
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Table 1 Acupuncture treatment details based on the STRICTA checklist [11]
Item Detail
1.Acupuncture rationale 1a) Style of acupuncture
- electro-acupuncture
1b) Reasoning for treatment provided, based on historical context, literature sources, and/or consensus
methods, with references where appropriate
- electro-acupuncture treatment based on the theory of TCM, literature sources, and clinical
experience in acupuncture and CINV, such as references [16] and [17].
1c) Extent to which treatment was varied
- The treatment was not varied.
2. Details of needling 2a) Number of needle insertions per subject per session (mean and range where relevant)
- From 2 to 3.
2b) Names (or location if no standard name) of points used (uni/bilateral)
- Four points used: ST36 (bilateral); PC6 (bilateral) ;CV12(unilateral); CV13 (unilateral).
2c) Depth of insertion, based on a specified unit of measurement, or on a particular tissue level
- PC6: 0.5 body-inches; ST36: 1-1.5 body-inches; CV12 and CV13: 1-1.5 body-inches.
2d) Response sought (e.g., de qi or muscle twitch response)
- ‘De qi’ sensation will be achieved by lifting and thrusting combined with twirling and rotating the needles.
2e) Needle stimulation (e.g., manual, electrical)
- Electrical stimulation: the frequency is 2/10 Hz, and the intensity of stimulation is adjusted according to the patient’s
tolerance (maximum of 10 mA).
2f) Needle retention time
- Thirty minutes
2g) Needle type (diameter, length, and manufacturer or material)
- A disposable stainless steel acupuncture needle, 0.25mm × 40 mm (Huatuo, Suzhou Medical Co. Ltd., Jiangsu, China).
3.Treatment regimen 3a) Number of treatment sessions
- Four treatment sessions in acupuncture groups.
3b) Frequency and duration of treatment sessions
- Once daily for 4 days, 30 minutes for each session.
4. Other components
of treatment
4a) Details of other interventions administered to the acupuncture group
(e.g., moxibustion, cupping, herbs, exercises, lifestyle advice)
- No other interventions.
4b) Setting and context of treatment, including instructions to practitioners, and information and explanations to patients
- University hospitals.
- Participants will be informed about acupuncture treatment in the study as follows: “In this study, eletroacupuncture
for CINV will be used based on traditional Chinese medicine.”
5.Practitioner
background
5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice, other
relevant experience)
- The participating acupuncturists have all majored in acupuncture, have an acupuncture degree, and are qualified
doctors of Tradition Chinese Medicine. All have at least 3 years of experience, and will have been trained in the standard
operating procedure of electro-acupuncture on CINV. Thus, they are able to provide identical acupuncture treatment in
accordance with a pre-defined protocol.
6. Control or comparator
interventions
6a) Rationale for the control or comparator in the context of the research question, with sources that justify this choice
- The control group is supplied with standard antiemetic alone, so as to provide patients with conventional treatment
for CINV.
6b) Precise description of the control or comparator. If sham acupuncture or any other type of acupuncture-like control is
used, provide details as for items 1 to 3 above.
- Participants in the control group will not receive acupuncture treatment.
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Outcome measures
The observation period will cover the day before
chemotherapy (day 0) to the fifth day of chemotherapy
(day 5). Follow-ups will be conducted from the sixth
day (day 6) to the twenty first day (day 21) of chemo-
therapy. Participants will be asked to keep CINV diaries
from the sixth day (day 6) to the twentieth day of
chemotherapy (day 20).
Primary outcome measures
The primary outcome measures are as follows:
(1)Frequency of nausea and vomiting: total nausea and
vomiting episodes per person over the 6-day study
period will be recorded. The frequency of nausea
and vomiting is the most valuable measurement for
evaluation.
(2)Grading of nausea and vomiting: nausea and
vomiting will be graded by Common Terminology
Criteria for Adverse Events Version 4.0 [12].
(3)Rhodes Index of Nausea, Vomiting and Retching:
nausea, vomiting and retching will be measured as
separate entities by Rhodes Index of Nausea,
Vomiting and Retching, which have 8 items with 5-
point Likert scales. The frequency and distress of all
entities are measured, as well as the duration of
nausea and the amount of vomitius. [13]
Secondary outcome measures
Secondary outcome measures include the following:
(1)Grading of constipation and diarrhea: constipation and
diarrhea will be evaluated by Common Terminology
Criteria for Adverse Events Version 4.0 [12].
(2)Electrogastrogram: gastrointestinal motility will be
monitored by electrogastrogram.
(3)Assessment of quality of life: the Functional
Assessment of Cancer Therapy- General (FACT-G)
[14] will be applied to assess four domains of patient
quality of life, including physical, social/family,
emotional, and functional well-being.
(4)Assessment of anxiety and depression: the Hospital
Anxiety and Depression Scale [15] will be used to
assess anxiety with seven items and depression with
another seven items.
(5)Other adverse effects, including appetite, will be
assessed by Common Terminology Criteria for
Adverse Events Version 4.0 [12].
Table 2 The schedule of enrollment, interventions, and assessments
Study period
Enrolment Allocation Post-allocation Close-out







Experimental group I √ √ √ √
Experimental group II √ √ √ √
Experimental group III √ √ √ √
Assessments
Baseline variables √ √
The frequency of nausea and vomiting √ √ √ √ √ √ √ √
The grading of nausea and vomiting √ √ √ √ √ √ √ √
Rhodes Index of nausea, vomiting and retching √ √ √ √ √ √ √ √
The grading of constipation and diarrhea √ √ √
eletrogastrogram √ √ √
quality of life √ √ √
anxiety and depression √ √ √
Other adverse effect during the chemotherapy √ √
The adverse effects of acupuncture √ √ √ √
t0, the day before chemotherapy; t1-t5, the first day to the fifth day of chemotherapy; t6-t21, the sixth day to the 21st day of chemotherapy
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Sample size calculation
A sample size calculation was performed based on the
result of a trial by Shen J [8] and the results of a pilot
study. To detect a significant difference between any two
groups with a power of 90 % and type I error of 5 %, the
calculated number of patients is 192. Considering a 20 %
drop-out rate, the total sample size needs 240 patients
and 60 patients in each group.
Statistical analysis
Statistical analysis will also be performed by the Clinical
Evaluation Center at China Academy of Chinese Medical
Science. The statistician is blinded from the allocation of
groups. The Kruskal-Wallis test will be employed in the
analysis of skewed distribution data. Chi-square analysis
will be used for categorical variables, and Analysis of
variance (ANOVA) for numerical variables. Repeated
measures analysis will be used in the different time point
assessment. A P value less than 0.05 is regarded as
statistically significant.
Data management
To promote data quality, the data will be collected by
well-trained assessor and the double entry of the data
will be implemented by clinical research coordinators.
Safety
Participants will also be monitored for any adverse
events, including swelling, pain, bruise at the sites of
needle insertion, or discomfort, palpitation, dizziness,
etcetera after acupuncture treatment. Adverse effects
will be recorded in the case report forms (CRF).
Quality control
All researchers will be required to undergo special train-
ing classes to guarantee the quality of the study. The
training classes will introduce researchers to the trial’s
details. For example, researchers will be trained to use
the central randomized system, to fully understand the
inclusion and exclusion criteria, and to fill in the CRFs.
Additionally, clinical monitors will also check the trial
processes and CRFs. Patient drop-outs and their reasons
will be fully recorded.
Ethics and dissemination
Medical Ethics Committees at Tianjin University of
Traditional Chinese Medicine has approved this
protocol (approval number is TJUTCM-EC20140006
and). Patients’ data will be stored securely and the
results of the present study will be published in a
peer-reviewed journal.
Discussion
This study protocol expands current literature regarding
the efficacy of acupuncture on CINV. Previous reviews
showed that acupoint stimulation has a certain effect on
CINV. However, the effects of different acupoint combi-
nations are inconsistent. We designed our trial to com-
pare the effects of distal-proximal point association and
local distribution point association.
More than 300 acupuncture points are located on the
body and each point has its own therapeutic indication.
The correct selection and combination of acupoints are
the keys to the curative effects of acupuncture [6]. Be-
fore developing the trial protocol, we screened a range
of published articles and ancient books. Our literature
search showed that PC6, ST36, and CV12 are the most
commonly used acupoints for managing CINV [16, 17].
We selected PC6 and ST36 as the distal acupoints, and
CV12 as the local acupoint. Based on the theory of
Chinese acupuncture, distal-proximal acupoint association
and local distribution point association are the two classic
methods for combining acupoints. Distal-proximal acu-
point association is also the most commonly used method
in clinical applications. In this trial, there are three differ-
ent acupuncture groups: “PC6 and CV12” and “ST36 and
CV12” are the two disal-proximal acupoint association
groups, and “CV12 and CV13” is the local distribu-
tion point association group. Therefore, we expect
that distal-proximal point association (“PC6 and
CV12” or “ST36 and CV12”) will have better effect
than local distribution point association (“CV12 and
CV13”). Furthermore, we can screen the most effect-
ive acupoint combination for clinical application from
these three groups.
Although the manipulators and participants cannot
be blinded to the group allocation in this study, all
outcome measures will be administered and collected
by a blinded estimator, and statisticians blinded to
group assignment will perform data analysis. With
respect to clinical quality control, the manipulators,
estimators and statisticians will work independently to
reduce the adverse impacts of artificial factors on
data. A third party has been invited to manage data
independently and to design a central randomization
system for minimizing bias and enhancing clinical
research quality.
In conclusion, the results of this trial are expected
to assess the clinical efficacy and safety of distal-
proximal point association and the local distribution
point association by electro-acupuncture in the man-
agement of CINV.
Trial status
The first participant was recruited on 26 June 2015. This
study is currently recruiting participants.
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